U. Bode

8k citations

139 papers · 6.3k · 1 hit paper · h-index 43

Impact in

Genetics top 0.5%
- Glioma Diagnosis and Treatment
Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis

Papers in

Genetics 28
- Glioma Diagnosis and Treatment 25
Oncology 20
- Neutropenia and Cancer Infections 13

Co-authors: Gudrun Fleischhack (41 shared papers)Arne Simon (28 shared papers)Ulrich Jaehde (9 shared papers)Carola Hasan (23 shared papers)Norbert M. Graf (11 shared papers)Stefan Rutkowski (12 shared papers)Sandra Vezmar (6 shared papers)Monika Warmuth‐Metz (9 shared papers)
Journals: Journal of Neuro-Oncology (6 papers)Journal of Clinical Oncology (4 papers)Neuro-Oncology (4 papers)European Journal of Pediatrics (3 papers)Blood (3 papers)
Partner nations: Germany Austria Switzerland

In The Last Decade

U. Bode

130 papers receiving 5.9k citations

U. Bode's Hit Papers

align trajectories log scale

Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95 2008 · 499 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2008 Blood

Peers

Countries citing papers authored by U. Bode

Since Specialization

Citations

This map shows the geographic impact of U. Bode's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by U. Bode with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites U. Bode more than expected).

Fields of papers citing papers by U. Bode

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by U. Bode. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by U. Bode. The network helps show where U. Bode may publish in the future.

Co-authors

The 25 scholars most cited alongside U. Bode, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with U. Bode Line = papers co-authored together U. Bode links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 139 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Treatment of Early Childhood Medulloblastoma by Postoperative Chemotherapy Alone New England Journal of Medicine ·Stefan Rutkowski, U. Bode, Frank Deinlein, Holger Ottensmeier, Monika Warmuth‐Metz, Niels Soerensen, Norbert M. Graf, Angela Emser	2005	602
2	Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95 Blood ·Anja Möricke, Alfred Reiter, Martin Zimmermann, Helmut Gadner, Martin Stanulla, Michael Dördelmann, Lutz Löning, Rita Beier Hit paper breakdown →	2008	499
3	Primary Central Nervous System Lymphoma: Results of a Pilot and Phase II Study of Systemic and Intraventricular Chemotherapy With Deferred Radiotherapy Journal of Clinical Oncology ·Hendrik Pels, Ingo G.H. Schmidt‐Wolf, Axel G. Glasmacher, H. Schulz, Andreas Engert, Volker Diehl, Anton Zellner, Gabriele Schackert	2003	342
4	Biochemical and Clinical Aspects of Methotrexate Neurotoxicity Chemotherapy ·Sandra Vezmar, Achim Becker, U. Bode, Ulrich Jaehde	2003	226
5	Pretreatment prognostic factors and treatment results in children with hepatoblastoma Cancer ·Jörg Fuchs, Jana Rydzynski, Dietrich von Schweinitz, U. Bode, Hartmut Hecker, Peter Weinel, Dietrich Bürger, D. Harms	2002	201
6	Medical Honey for Wound Care—Still the ‘Latest Resort’? Evidence-based Complementary and Alternative Medicine ·Arne Simon, Kirsten S. Traynor, Kai Santos, Gisela Blaser, U. Bode, Peter C. Molan	2007	176
7	Methotrexate pharmacokinetics and prognosis in osteosarcoma. Journal of Clinical Oncology ·Norbert M. Graf, K. Winkler, M Betlemovic, Nicola Fuchs, U. Bode	1994	143
8	Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters Journal of Clinical Oncology ·Andre Oscar von Bueren, Rolf‐Dieter Kortmann, Katja von Hoff, Carsten Friedrich, Martin Mynarek, Klaus Müller, Tobias Goschzik, Anja zur Mühlen	2016	137
9	Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure British Journal of Cancer ·Doris NGampolo, RG Melton, Carola Hasan, Andreas Zoubek, Günter Henze, U. Bode, G. Fleischhack +1 other	2005	126
10	Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma European Journal of Cancer ·Dietrich von Schweinitz, D. J. Byrd, Hartmut Hecker, Peter Weinel, U. Bode, Dietrich Bürger, Rolf Erttmann, D. Harms	1997	123
11	Complete resection before development of drug resistance is essential for survival from advanced hepatoblastoma—A report from the German Cooperative Pediatric Liver Tumor Study HB-89 Journal of Pediatric Surgery ·Dietrich von Schweinitz, Hartmut Hecker, D. Harms, U. Bode, Peter Weinel, Dietrich Bürger, R. Erttmann, Hermann Mildenberger	1995	122
12	Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy Neuro-Oncology ·Stefan Rutkowski, Nicolas U. Gerber, Katja von Hoff, Astrid Katharina Gnekow, U. Bode, Norbert M. Graf, Frank Berthold, Guenter Henze	2009	122
13	Human metapneumovirus infections cause similar symptoms and clinical severity as respiratory syncytial virus infections European Journal of Pediatrics ·Anja Wilkesmann, Oliver Schildgen, Anna Maria Eis‐Hübinger, Tilman Geikowski, Thomas Glatzel, M. J. Lentze, U. Bode, Arne Simon	2006	121
14	Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumour necrosis factor receptor II British Journal of Haematology ·Gudrun Fleischhack, Isabell Kambeck, Dubravka Cipic, Carola Hasan, U. Bode	2000	105
15	Results of the SIOP 93-01/GPOH Trial and Study for the Treatment of Patients with Unilateral Nonmetastatic Wilms Tumor Klinische Pädiatrie ·Harald Reinhard, Oliver Semler, Dietrich Bürger, U. Bode, Michael Flentje, Ulrich Göbel, Peter Gutjahr, Ivo Leuschner	2004	102
16	Insulin-Like Growth Factor II Is Involved in the Proliferation Control of Medulloblastoma and Its Cerebellar Precursor Cells American Journal Of Pathology ·Wolfgang Hartmann, Arend Koch, Hendrik Brune, Anke Waha, Ulrich Schüller, Indra Dani, Dorota Denkhaus, Wilhelma Langmann	2005	101
17	Pharmacokinetics Following Intraventricular Administration of Chemotherapy in Patients with Neoplastic Meningitis Clinical Pharmacokinetics ·Gudrun Fleischhack, Ulrich Jaehde, U. Bode	2005	98
18	CNS late effects after ALL therapy in childhood. Part I: Neuroradiological findings in long-term survivors of childhood ALL—an evaluation of the interferences between morphology and neuropsychological performance Medical and Pediatric Oncology ·Holger Hertzberg, Walter Josef Huk, Michael A. Ueberall, Thorsten Langer, W Meier, Roland E. Dopfer, Martin Skalej, Herwig Lackner	1997	96
19	Healthcare-associated infections in pediatric cancer patients: results of a prospective surveillance study from university hospitals in Germany and Switzerland BMC Infectious Diseases ·Arne Simon, Roland A. Ammann, U. Bode, Gudrun Fleischhack, Hans-Martin Wenchel, Dorothee Schwamborn, Chara Gravou-Apostolatou, Paul‐Gerhardt Schlegel	2008	93
20	Long‐term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma Annals of Neurology ·Annika Juergens, Hendrik Pels, Sabine Rogowski, Klaus Fließbach, Axel G. Glasmacher, Andreas Engert, Marcel Reiser, Volker Diehl	2009	87

About U. Bode

U. Bode is a scholar working on Genetics, Oncology, Emergency Medical Services, Neurology and Public Health, Environmental and Occupational Health, having authored 139 papers that have together received 6.3k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (25 papers), Acute Lymphoblastic Leukemia research (16 papers), Neutropenia and Cancer Infections (13 papers), Central Venous Catheters and Hemodialysis (8 papers), Childhood Cancer Survivors' Quality of Life (7 papers), Sarcoma Diagnosis and Treatment (7 papers), CNS Lymphoma Diagnosis and Treatment (7 papers) and Respiratory viral infections research (6 papers). The work is most often cited by research in Genetics (1.4k citations), Hepatology (427 citations), Neurology (588 citations), Emergency Medical Services (235 citations) and Oncology (575 citations). U. Bode has collaborated with scholars based in Germany, Austria and Switzerland. Frequent co-authors include Gudrun Fleischhack, Arne Simon, Ulrich Jaehde, Carola Hasan, Norbert M. Graf, Stefan Rutkowski, Sandra Vezmar, Monika Warmuth‐Metz, Achim Becker and Dietrich von Schweinitz. Their work appears in journals such as Journal of Neuro-Oncology, Journal of Clinical Oncology, Neuro-Oncology, European Journal of Pediatrics and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

U. Bode

Impact in

Papers in i

In The Last Decade

U. Bode

U. Bode's Hit Papers

Peers

Countries citing papers authored by U. Bode

Fields of papers citing papers by U. Bode

All Works

About U. Bode

Explore authors with similar magnitude of impact

Papers in